

Baxter International Inc.
Key Product Line Sales -- US/International
Period Ending March 31, 2005
(unaudited)

(\$ in millions)	Q1 2005			Q1 2004			% Growth		
	US	International	Total	US	International	Total	US	International	Total
BioScience									
Recombinants	\$145	\$199	\$344	\$141	\$151	\$292	3%	32%	18%
Plasma Proteins ¹	112	147	259	114	124	238	(2%)	19%	9%
Antibody Therapy	48	41	89	43	37	80	12%	11%	11%
Transfusion Therapies	65	68	133	65	75	140	0%	(9%)	(5%)
Other ²	28	49	77	22	38	60	27%	29%	28%
Total BioScience	\$398	\$504	\$902	\$385	\$425	\$810	3%	19%	11%
Medication Delivery									
IV Therapies ³	\$94	\$202	\$296	\$103	\$179	\$282	(9%)	13%	5%
Drug Delivery	139	65	204	126	62	188	10%	5%	9%
Infusion Systems	155	75	230	126	62	188	23%	21%	22%
Anesthesia	158	73	231	171	71	242	(8%)	3%	(5%)
Other ⁴	6	11	17	8	18	26	(25%)	(39%)	(35%)
Total Medication Delivery ⁵	\$552	\$426	\$978	\$534	\$392	\$926	3%	9%	6%
Renal									
PD Therapy	\$60	\$314	\$374	\$63	\$282	\$345	(5%)	11%	8%
HD Therapy	32	94	126	34	90	124	(6%)	4%	2%
Other	2	1	3	3	1	4	(33%)	0%	(25%)
Total Renal	\$94	\$409	\$503	\$100	\$373	\$473	(6%)	10%	6%
TOTAL BAXTER	\$1,044	\$1,339	\$2,383	\$1,019	\$1,190	\$2,209	2%	13%	8%

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery (Tisseel) and other plasma-based products.

² Principally includes vaccines and non-plasma-based biosurgery products (FloSeal & CoSeal).

³ Principally includes intravenous solutions and nutritional products.

⁴ Principally includes other hospital-distributed products.

⁵ Sales of oncology products, which were previously included in Other, are now reported in Drug Delivery, Infusion Systems or Anesthesia, depending on the product. All prior year sales data has been reclassified to reflect this change.